No Sales Model Left Behind: Novartis Joins Firms In Changing Market Focus
Executive Summary
Novartis is joining the horde of pharmaceutical companies that are revamping their sales and marketing organizations in response to a U.S. market that is rapidly changing, at varying paces in different regions
You may also be interested in...
Novartis Revamps U.S. Pharma Unit, With New CEO Andre Wyss
Novartis is reorganizing its U.S. pharmaceutical business, effective May 1, a move that includes the departure of Ludwig Hanston, who ran the unit for the past two years, and the elimination of nearly 400 positions mostly at U.S. headquarters, the company's Global Pharma CEO David Epstein told employees in a memo distributed on April 13
Novartis Revamps U.S. Pharma Unit, With New CEO Andre Wyss
Novartis is reorganizing its U.S. pharmaceutical business, effective May 1, a move that includes the departure of Ludwig Hanston, who ran the unit for the past two years, and the elimination of nearly 400 positions mostly at U.S. headquarters, the company's Global Pharma CEO David Epstein told employees in a memo distributed on April 13
Novartis Names Andre Wyss To Run Its North American And U.S. Pharma Business
The 25-year Novartis veteran succeeds Ludwig Hantson, who was simultaneously named as corporate vice president at Baxter International.